Nouscom

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf‚Ä™ Cancer Immunotherapy Developed Using Nouscom‚Ä™s Proprietary Viral Vector Platform

BASEL, Switzerland – 17th May 2022 – Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Janssen Research & Development, LLC (Janssen) received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic…
Bäumleingasse, 18 CH-4051 Basel

+41 61 201 18 31